Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Nature Reviews Clinical Oncology

Volumn 15, Issue 4, 2018, Pages 234-248

  Johnson, Daniel E ^a   O'Keefe, Rachel A ^a   Grandis, Jennifer R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C 188 9; DANVATIRSEN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; JANUS KINASE INHIBITOR; OPB 31121; OPB 51602; PROTEIN INHIBITOR; SILTUXIMAB; STAT3 PROTEIN; TOCILIZUMAB; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

CANCER IMMUNOTHERAPY; CANCER RESEARCH; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECT; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HUMANS; INTERLEUKIN-6; JANUS KINASES; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, CHIMERIC ANTIGEN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR MICROENVIRONMENT;

EID: 85044065443     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2018.8     Document Type: Review

References (255)

1. Kumari, N., Dwarakanath, B. S., Das, A. & Bhatt, A. N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37, 11553-11572 (2016).
2. Kusaba, T. et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol. Rep. 15, 1445-1451 (2006).
3. Chen, Y., et al. STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J. Breast Cancer 16, 40-49 (2013).
4. Macha, M. A. et al. Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck 33, 482-489 (2011).
5. Ludwig, H., Nachbaur, D. M., Fritz, E., Krainer, M. & Huber, H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77, 2794-2795 (1991).
6. Buchert, M., Burns, C. J. & Ernst, M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 35, 939-951 (2016).
7. Tartaglia, M. et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34, 148-150 (2003).
8. Zhang, X. et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc. Natl Acad. Sci. USA 104, 4060-4064 (2007).
9. Peyser, N. D. et al. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene 35, 1163-1169 (2016).
10. Peyser, N. D. et al. Loss-of-function PTPRD mutations lead to increased STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. PLoS ONE 10, e0135750 (2015).
11. Lui, V. W. et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc. Natl Acad. Sci. USA 111, 1114-1119 (2014).
12. Nozawa, H., Chiu, C. & Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103, 12493-12498 (2006).
13. Nagasaki, T. et al. Interleukin-6 released by colon cancer-Associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br. J. Cancer 110, 469-478 (2014).
14. Bournazou, E. & Bromberg, J. Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT 2, e23828 (2013).
15. Walter, M., Liang, S., Ghosh, S., Hornsby, P. J. & Li, R. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28, 2745-2755 (2009).
16. Chang, Q. et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15, 848-862 (2013).
17. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
18. Yu, H. & Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4, 97-105 (2004).
19. Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314-1321 (2005).
20. Yu, H., Kortylewski, M. & Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51 (2007).
21. Harris, T. J. et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179, 4313-4317 (2007).
22. Herrmann, A. et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 70, 7455-7464 (2010).
23. Kujawski, M. et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 70, 9599-9610 (2010).
24. Siegel, A. M. et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35, 806-818 (2011).
25. Iwata-Kajihara, T. et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J. Immunol. 187, 27-36 (2011).
26. Gotthardt, D. et al. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 124, 2370-2379 (2014).
27. Hossain, D. M. et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood 123, 15-25 (2014).
28. Kortylewski, M. & Yu, H. Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol. 20, 228-233 (2008).
29. Lee, H., Pal, S. K., Reckamp, K., Figlin, R. A. & Yu, H. STAT3: a target to enhance antitumor immune response. Curr. Top. Microbiol. Immunol. 344, 41-59 (2011).
30. Lederle, W. et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int. J. Cancer 128, 2803-2814 (2011).
31. Mullberg, J. et al. IL-6 receptor independent stimulation of human gp130 by viral IL-6. J. Immunol. 164, 4672-4677 (2000).
32. Scheller, J., Chalaris, A., Schmidt-Arras, D. & Rose-John, S. The pro-And anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813, 878-888 (2011).
33. Hirano, T. et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73-76 (1986).
34. Kopf, M. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339-342 (1994).
35. Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448-457 (2015).
36. Ohshima, S. et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl Acad. Sci. USA 95, 8222-8226 (1998).
37. Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461-468 (1998).
38. Screpanti, I. et al. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. J. Exp. Med. 184, 1561-1566 (1996).
39. Garnero, P., Thompson, E., Woodworth, T. & Smolen, J. S. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 62, 33-43 (2010).
40. Nishimoto, N. et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95, 56-61 (2000).
41. Yoon, S. et al. NF-kappaB and STAT3 cooperatively induce IL6 in starved cancer cells. Oncogene 31, 3467-3481 (2012).
42. Campbell, I. L. et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J. Neurosci. 34, 2503-2513 (2014).
43. Rose-John, S., Scheller, J., Elson, G. & Jones, S. A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80, 227-236 (2006).
44. Wolf, J., Rose-John, S. & Garbers, C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70, 11-20 (2014).
45. Skiniotis, G., Boulanger, M. J., Garcia, K. C. & Walz, T. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat. Struct. Mol. Biol. 12, 545-551 (2005).
46. Honda, M. et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. 148, 2175-2180 (1992).
47. Novick, D., Engelmann, H., Wallach, D. & Rubinstein, M. Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 170, 1409-1414 (1989).
48. Baran, P., Nitz, R., Grotzinger, J., Scheller, J. & Garbers, C. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J. Biol. Chem. 288, 14756-14768 (2013).
49. Jones, S. A., Horiuchi, S., Topley, N., Yamamoto, N. & Fuller, G. M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 15, 43-58 (2001).
50. Diamant, M. et al. Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett. 412, 379-384 (1997).
51. Jostock, T. et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160-167 (2001).
52. Rose-John, S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int. J. Biol. Sci. 8, 1237-1247 (2012).
53. Haan, C., Kreis, S., Margue, C. & Behrmann, I. Jaks and cytokine receptors-An intimate relationship. Biochem. Pharmacol. 72, 1538-1546 (2006).
54. Ernst, M. & Jenkins, B. J. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 20, 23-32 (2004).
55. Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest. 109, 1139-1142 (2002).
56. Dorritie, K. A., McCubrey, J. A. & Johnson, D. E. STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 28, 248-257 (2014).
57. Takeda, K. et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA 94, 3801-3804 (1997).
58. Cimica, V., Chen, H. C., Iyer, J. K. & Reich, N. C. Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importin-beta1. PLoS ONE 6, e20188 (2011).
59. Benekli, M., Baumann, H. & Wetzler, M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol. 27, 4422-4432 (2009).
60. Ilaria, R. L. Jr., Van Etten, R. A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271, 31704-31710 (1996).
61. Stark, G. R., Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503-514 (2012).
62. Kim, E. et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839-852 (2013).
63. Sekine, Y. et al. Regulation of STAT3-mediated signaling by LMW-DSP2. Oncogene 25, 5801-5806 (2006).
64. Kim, D. J., Tremblay, M. L. & Digiovanni, J. Protein tyrosine phosphatases, TC-PTP, SHP1, and SHP2, cooperate in rapid dephosphorylation of Stat3 in keratinocytes following UVB irradiation. PLoS ONE 5, e10290 (2010).
65. Zhang, M. et al. Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J. Immunol. 186, 4716-4724 (2011).
66. Rokavec, M. et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest. 124, 1853-1867 (2014).
67. Wei, J. et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 73, 3913-3926 (2013).
68. Yang, Y. et al. MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis. Mol. Cancer 16, 141 (2017).
69. Chaluvally-Raghavan, P. et al. Direct upregulation of STAT3 by microRNA-551b-3p deregulates growth and metastasis of ovarian cancer. Cell Rep. 15, 1493-1504 (2016).
70. Wu, W. et al. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br. J. Cancer 108, 653-661 (2013).
71. Liu, S. et al. microRNA 221-And 222-mediated feedback loop maintains constitutive activation of NFkappaB and STAT3 in colorectal cancer cells. Gastroenterology 147, 847-859.e11 (2014).
72. Dethlefsen, C., Hojfeldt, G. & Hojman, P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res. Treat. 138, 657-664 (2013).
73. Kotowicz, B., Fuksiewicz, M., Jonska-Gmyrek, J., Bidzinski, M. & Kowalska, M. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Tumour Biol. 37, 1271-1278 (2016).
74. Chung, Y. C. & Chang, Y. F. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol. 83, 222-226 (2003).
75. Chen, M. F. et al. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol. Cancer 12, 26 (2013).
76. Jinno, T. et al. Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma. Oncol. Rep. 33, 2161-2168 (2015).
77. Riedel, F. et al. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res. 25, 2761-2765 (2005).
78. Maccio, A. & Madeddu, C. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications-A review. J. Mol. Med. 91, 1355-1368 (2013).
79. Sanguinete, M. M. M. et al. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol. Invest. 46, 677-688 (2017).
80. Miura, T. et al. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas 44, 756-763 (2015).
81. Culig, Z. & Puhr, M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol. Cell. Endocrinol. 360, 52-58 (2012).
82. Altundag, O., Altundag, K. & Gunduz, E. Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J. Clin. Oncol. 23, 1044 (2005).
83. Chang, C. H. et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int. J. Cancer 132, 1977-1985 (2013).
84. Watt, D. G., Horgan, P. G. & McMillan, D. C. Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review. Surgery 157, 362-380 (2015).
85. Wu, C. T., Chen, M. F., Chen, W. C. & Hsieh, C. C. The role of IL-6 in the radiation response of prostate cancer. Radiat. Oncol. 8, 159 (2013).
86. Knupfer, H. & Preiss, R. Serum interleukin-6 levels in colorectal cancer patients-A summary of published results. Int. J. Colorectal Dis. 25, 135-140 (2010).
87. Duffy, S. A. et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113, 750-757 (2008).
88. Gao, J., Zhao, S. & Halstensen, T. S. Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma. Oncol. Rep. 35, 3265-3274 (2016).
89. Sansone, P. et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117, 3988-4002 (2007).
90. Becker, C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501 (2004).
91. Becker, C. et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 4, 217-220 (2005).
92. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-Associated cancer. Cancer Cell 15, 103-113 (2009).
93. Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846-3856 (2007).
94. Lesina, M. et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456-469 (2011).
95. Sullivan, N. J. et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28, 2940-2947 (2009).
96. Yadav, A., Kumar, B., Datta, J., Teknos, T. N. & Kumar, P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol. Cancer Res. 9, 1658-1667 (2011).
97. Baltgalvis, K. A. et al. Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R393-R401 (2008).
98. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
99. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
100. Rebouissou, S. et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204 (2009).
101. Fishman, D. et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102, 1369-1376 (1998).
102. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005).
103. Jones, A. V. et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106, 2162-2168 (2005).
104. Walters, D. K. et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10, 65-75 (2006).
105. Bose, P. & Verstovsek, S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood 130, 115-125 (2017).
106. Senkevitch, E. & Durum, S. The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine 98, 33-41 (2017).
107. Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005).
108. James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (2005).
109. Lacronique, V. et al. TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997).
110. Kan, Z. et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23, 1422-1433 (2013).
111. Frank, D. A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251, 199-210 (2007).
112. Roeser, J. C., Leach, S. D. & McAllister, F. Emerging strategies for cancer immunoprevention. Oncogene 34, 6029-6039 (2015).
113. Chen, C. L. et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol. Cancer 7, 78 (2008).
114. Sonnenblick, A. et al. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin. Transl Oncol. 14, 232-236 (2012).
115. Schaefer, L. K., Ren, Z., Fuller, G. N. & Schaefer, T. S. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21, 2058-2065 (2002).
116. Takemoto, S. et al. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br. J. Cancer 101, 967-972 (2009).
117. Zhang, H. F. et al. The opposing function of STAT3 as an oncoprotein and tumor suppressor is dictated by the expression status of STAT3beta in esophageal squamous cell carcinoma. Clin. Cancer Res. 22, 691-703 (2016).
118. Geiger, J. L., Grandis, J. R. & Bauman, J. E. The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations. Oral Oncol. 56, 84-92 (2016).
119. Li, S. et al. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS ONE 8, e81657 (2013).
120. Wang, Y., Qu, A. & Wang, H. Signal transducer and activator of transcription 4 in liver diseases. Int. J. Biol. Sci. 11, 448-455 (2015).
121. Suh, Y. A., Jo, S. Y., Lee, H. Y. & Lee, C. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. Int. J. Oncol. 46, 1405-1411 (2015).
122. Sahu, R. P. & Srivastava, S. K. The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. J. Natl Cancer Inst. 101, 176-193 (2009).
123. Wang, Z. et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. PLoS ONE 8, e75788 (2013).
124. Subramaniam, K. S. et al. Cancer-Associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway. Am. J. Cancer Res. 6, 200-213 (2016).
125. Bar-Natan, M., Nelson, E. A., Xiang, M. & Frank, D. A. STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAKSTAT 1, 55-64 (2012).
126. Bromberg, J. F. et al. Stat3 as an oncogene. Cell 98, 295-303 (1999).
127. Ho, P. L., Lay, E. J., Jian, W., Parra, D. & Chan, K. S. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res. 72, 3135-3142 (2012).
128. Kryczek, I. et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40, 772-784 (2014).
129. Leong, P. L. et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl Acad. Sci. USA 100, 4138-4143 (2003).
130. Li, Y. et al. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 67, 8494-8503 (2007).
131. Fukuda, A. et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19, 441-455 (2011).
132. Abdulghani, J. et al. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172, 1717-1728 (2008).
133. Kim, D. J., Angel, J. M., Sano, S. & DiGiovanni, J. Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis. Oncogene 28, 950-960 (2009).
134. Spitzner, M. et al. STAT3: a novel molecular mediator of resistance to chemoradiotherapy. Cancers 6, 1986-2011 (2014).
135. Sen, M. et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin. Cancer Res. 18, 4986-4996 (2012).
136. Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogene-Addicted cancer cells. Cancer Cell 26, 207-221 (2014).
137. Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L. & Struhl, K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 39, 493-506 (2010).
138. Li, H. S. et al. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci. Signal. 9, ra94 (2016).
139. Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48-54 (2004).
140. Kujawski, M. et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118, 3367-3377 (2008).
141. Koskela, H. L. et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 366, 1905-1913 (2012).
142. Kucuk, C. et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat. Commun. 6, 6025 (2015).
143. Andersson, E. et al. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia 30, 1204-1208 (2016).
144. Grandis, J. R. et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J. Clin. Invest. 102, 1385-1392 (1998).
145. Ozawa, Y. et al. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk. Res. 32, 893-903 (2008).
146. Grabner, B. et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat. Commun. 6, 6285 (2015).
147. Lei, Y. et al. Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation. Mol. Cancer 16, 170 (2017).
148. Musteanu, M. et al. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 138, 1003-1011.e5 (2010).
149. Hsiao, J. R. et al. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br. J. Cancer 89, 344-349 (2003).
150. Gordziel, C., Bratsch, J., Moriggl, R., Knosel, T. & Friedrich, K. Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br. J. Cancer 109, 138-146 (2013).
151. Setsu, N. et al. Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis. Int. J. Cancer 132, 109-115 (2013).
152. van Rhee, F. et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J. Clin. Oncol. 28, 3701-3708 (2010).
153. van Rhee, F. et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 15, 966-974 (2014).
154. Kurzrock, R. et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin. Cancer Res. 19, 3659-3670 (2013).
155. Hunsucker, S. A. et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br. J. Haematol. 152, 579-592 (2011).
156. Suzuki, K. et al. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. Int. J. Hematol. 101, 286-294 (2015).
157. Orlowski, R. Z. et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am. J. Hematol. 90, 42-49 (2015).
158. Voorhees, P. M. et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 161, 357-366 (2013).
159. San-Miguel, J. et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123, 4136-4142 (2014).
160. Shah, J. J. et al. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 6, e396 (2016).
161. Coward, J. et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17, 6083-6096 (2011).
162. Cavarretta, I. T. et al. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv. Exp. Med. Biol. 617, 547-555 (2008).
163. Song, L. et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J. Thorac Oncol. 9, 974-982 (2014).
164. Karkera, J. et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 71, 1455-1465 (2011).
165. Dorff, T. B. et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res. 16, 3028-3034 (2010).
166. Fizazi, K. et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur. J. Cancer 48, 85-93 (2012).
167. Rossi, J. F. et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br. J. Cancer 103, 1154-1162 (2010).
168. Angevin, E. et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 20, 2192-2204 (2014).
169. Liu, X., Jones, G. W., Choy, E. H. & Jones, S. A. The biology behind interleukin-6 targeted interventions. Curr. Opin. Rheumatol 28, 152-160 (2016).
170. Finkel, K. A. et al. IL-6 inhibition with MEDI5117 decreases the fraction of head and neck cancer stem cells and prevents tumor recurrence. Neoplasia 18, 273-281 (2016).
171. Zhong, H. et al. Novel IL6 antibody sensitizes multiple tumor types to chemotherapy including trastuzumab-resistant tumors. Cancer Res. 76, 480-490 (2016).
172. Yanaihara, N. et al. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol. Carcinog. 55, 832-841 (2016).
173. Goumas, F. A. et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int. J. Cancer 137, 1035-1046 (2015).
174. Dijkgraaf, E. M. et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-Alpha2b in patients with recurrent epithelial ovarian cancer. Ann. Oncol. 26, 2141-2149 (2015).
175. Matsumoto, S. et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-Associated premalignant cancer in a murine model. J. Immunol. 184, 1543-1551 (2010).
176. Brooks, G. D. et al. IL6 trans-signaling promotes KRAS-driven lung carcinogenesis. Cancer Res. 76, 866-876 (2016).
177. Hemmann, U. et al. Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem. 271, 12999-13007 (1996).
178. Gerhartz, C. et al. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J. Biol. Chem. 271, 12991-12998 (1996).
179. Meyer, D. M. et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J. Inflamm. 7, 41 (2010).
180. Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495-507 (2012).
181. van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508-519 (2012).
182. Lee, E. B. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377-2386 (2014).
183. Hodge, J. A. et al. The mechanism of action of tofacitinib-An oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin. Exp. Rheumatol 34, 318-328 (2016).
184. Bachelez, H. et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386, 552-561 (2015).
185. Sandborn, W. J. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723-1736 (2017).
186. Panes, J. et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut 66, 1049-1059 (2017).
187. Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799-807 (2012).
188. Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787-798 (2012).
189. Harrison, C. N. et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib versus best available therapy for myelofibrosis. Leukemia 30, 1701-1707 (2016).
190. Neubauer, H. et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409 (1998).
191. Verstovsek, S. et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br. J. Haematol. 161, 508-516 (2013).
192. Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426-435 (2015).
193. Passamonti, F. et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 18, 88-99 (2017).
194. Komrokji, R. S. et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 125, 2649-2655 (2015).
195. Verstovsek, S. et al. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J. Hematol. Oncol. 9, 137 (2016).
196. Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487-497 (2009).
197. Xin, H. et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71, 6601-6610 (2011).
198. Sen, M. et al. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia 17, 256-264 (2015).
199. Lee, J. H. et al. The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. Clin. Cancer Res. 19, 6777-6786 (2013).
200. Tavallai, M., Booth, L., Roberts, J. L., Poklepovic, A. & Dent, P. Rationally repurposing ruxolitinib (Jakafi ) as a solid tumor therapeutic. Front. Oncol. 6, 142 (2016).
201. Plimack, E. R. et al. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 18, 819-820 (2013).
202. Loh, M. L. et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr. Blood Cancer 62, 1717-1724 (2015).
203. Hurwitz, H. I. et al. Double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J. Clin. Oncol. 33, 4039-4047 (2015).
204. Wong, A. L. A. et al. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin. Investig. Drugs 26, 883-887 (2017).
205. Turkson, J. et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276, 45443-45455 (2001).
206. Turkson, J. et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 3, 261-269 (2004).
207. Mandal, P. K. et al. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J. Med. Chem. 54, 3549-3563 (2011).
208. Auzenne, E. J. et al. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J. Exp. Ther. Oncol. 10, 155-162 (2012).
209. Schust, J., Sperl, B., Hollis, A., Mayer, T. U. & Berg, T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13, 1235-1242 (2006).
210. Siddiquee, K. et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. Sci. USA 104, 7391-7396 (2007).
211. Song, H., Wang, R., Wang, S. & Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl Acad. Sci. USA 102, 4700-4705 (2005).
212. Zhang, X. et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl Acad. Sci. USA 109, 9623-9628 (2012).
213. Chen, C. L. et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 7, 111 (2007).
214. Fuh, B. et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br. J. Cancer 100, 106-112 (2009).
215. Hussain, S. F. et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 67, 9630-9636 (2007).
216. Pan, Y., Zhou, F., Zhang, R. & Claret, F. X. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo-And radio-sensitivity in nasopharyngeal carcinoma. PLoS ONE 8, e54565 (2013).
217. Zhang, X. et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res. 73, 1922-1933 (2013).
218. Zhang, X. et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol. 79, 1398-1409 (2010).
219. Ashizawa, T. et al. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int. J. Oncol. 38, 1245-1252 (2011).
220. Matsuno, K. et al. Identification of a new series of STAT3 inhibitors by virtual screening. ACS Med. Chem. Lett. 1, 371-375 (2010).
221. Chen, H. et al. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur. J. Med. Chem. 62, 498-507 (2013).
222. Brambilla, L. et al. Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). Mol. Oncol. 9, 1194-1206 (2015).
223. Hayakawa, F. et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-Addictive oncokinases. Blood Cancer J. 3, e166 (2013).
224. Kim, M. J. et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 335, 145-152 (2013).
225. Bendell, J. C. et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother. Pharmacol. 74, 125-130 (2014).
226. Oh, D. Y. et al. Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res. Treat. 47, 607-615 (2015).
227. Okusaka, T. et al. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol. Res. 45, 1283-1291 (2015).
228. Wong, A. L. et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann. Oncol. 26, 998-1005 (2015).
229. Ogura, M. et al. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci. 106, 896-901 (2015).
230. Bharadwaj, U. et al. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget 7, 26307-26330 (2016).
231. Xi, S., Gooding, W. E. & Grandis, J. R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24, 970-979 (2005).
232. Shen, J., Li, R. & Li, G. Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In Vivo 23, 237-243 (2009).
233. Sun, Z., Yao, Z., Liu, S., Tang, H. & Yan, X. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 211, 199-209 (2006).
234. Zhang, X., Zhang, J., Wang, L., Wei, H. & Tian, Z. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7, 149 (2007).
235. Zhang, X. et al. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo. Int. J. Mol. Med. 32, 623-628 (2013).
236. Chan, K. S. et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 114, 720-728 (2004).
237. Zhang, Q. et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood 127, 1687-1700 (2016).
238. Sen, M. et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2, 694-705 (2012).
239. Sen, M. et al. Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol. Med. 20, 46-56 (2014).
240. Hong, D. et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci. Transl Med. 7, 314ra185 (2015).
241. Burel, S. A. et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid. Ther. 23, 213-227 (2013).
242. Odate, S. et al. Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity. Clin. Cancer Res. 23, 1771-1784 (2017).
243. Okiyama, N. & Tanaka, R. Varied immuno-related adverse events induced by immune-check point inhibitors-Nivolumab-Associated psoriasiform dermatitis related with increased serum level of interleukin-6 [Japanese]. Nihon Rinsho Meneki Gakkai Kaishi 40, 95-101 (2017).
244. Tanaka, R. et al. Serum level of interleukin-6 is increased in nivolumab-Associated psoriasiform dermatitis and tumor necrosis factor-Alpha is a biomarker of nivolumab recativity. J. Dermatol. Sci. 86, 71-73 (2017).
245. Rotz, S. J. et al. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr. Blood Cancer 64, e26642 (2017).
246. Kim, S. T. et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann. Rheum. Dis. 76, 2061-2064 (2017).
247. Uemura, M. et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J. Hematol. Oncol. 9, 81 (2016).
248. Austin, J. W., Lu, P., Majumder, P., Ahmed, R. & Boss, J. M. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J. Immunol. 192, 4876-4886 (2014).
249. Thorn, M. et al. Tumor-Associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases. Cancer Gene Ther. 23, 188-198 (2016).
250. Zhang, N. et al. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int. J. Oncol. 49, 1360-1368 (2016).
251. Bu, L. L. et al. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. J. Dent. Res. 96, 1027-1034 (2017).
252. Atsaves, V. et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 31, 1633-1637 (2017).
253. Mace, T. A. et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67, 320-332 (2018).
254. Liu, H., Shen, J. & Lu, K. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. Biochem. Biophys. Res. Commun. 486, 239-244 (2017).
255. Lu, C., Talukder, A., Savage, N. M., Singh, N. & Liu, K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology 6, e1291106 (2017).